Advanced search
Start date
Betweenand
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

fficacy of House Dust Mite Sublingual Immunotherapy in Patients with Atopic Dermatitis: A Randomized, Double-Blind, Placebo-Controlled Tria

Full text
Author(s):
Show less -
Langer, Sarah Sella [1, 2] ; Cardili, Renata Nahas [2] ; Lima Melo, Janaina Michelle [2] ; Leme Ferriani, Mariana Paes [2] ; Moreno, Adriana Santos [2] ; Dias, Marina Mendonca [2] ; Bueno-Filho, Roberto [2] ; Candido Pocente, Renata Helena [2] ; Roxo-Junior, Persio [1] ; Silva, Jorgete [1] ; Pereira Valera, Fabiana Cardoso [3, 4] ; Coelho, Eduardo Barbosa [2] ; Santos Galvao, Clovis Eduardo [5] ; Carmona, Fabio [1] ; Aragon, Davi Casale [1] ; Arruda, Luisa Karla [2]
Total Authors: 16
Affiliation:
[1] Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Pediat, Ribeirao Preto, SP - Brazil
[2] Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Med, Ribeirao Preto, SP - Brazil
[3] Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Otorhinolaryngol, Ribeirao Preto, SP - Brazil
[4] Univ Sao Paulo, Ribeirao Preto Med Sch Hosp, Clin Res Unit, Ribeirao Preto, SP - Brazil
[5] Univ Sao Paulo, Div Clin Immunol & Allergy, Med Sch Hosp, Sao Paulo, SP - Brazil
Total Affiliations: 5
Document type: Journal article
Source: JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE; v. 10, n. 2, p. 539+, FEB 2022.
Web of Science Citations: 1
Abstract

BACKGROUND: Sensitization to house dust mites (HDMs) is frequent in patients with atopic dermatitis. OBJECTIVE: To investigate the efficacy of sublingual immunotherapy (SLIT) with Dermatophagoides pteronyssinus extract in patients with atopic dermatitis sensitized to HDM. METHODS: In this randomized, double-blind, placebo-controlled trial, we enrolled 91 patients 3 years or older, with SCORing Atopic Dermatitis (SCORAD) score greater than or equal to 15 and positive skin test result and/or IgE to D pter-onyssinus. Patients were stratified according to age (<12 and >= 12 years) to receive HDM SLIT or placebo for 18 months. Primary outcome was a greater than or equal to 15-point decrease in SCORAD score. Secondary outcomes were decreases in SCORAD and objective SCORAD, Eczema Area and Severity Index, visual analog scale for symptoms, and pruritus scale scores; Investigator's Global Assessment 0/1; and decrease greater than or equal to 4 points in Dermatology Life Quality Index. Background therapy was maintained. RESULTS: A total of 66 patients completed the study (35 HDM SLIT, 31 placebo). After 18 months, 74.2% and 58% of patients in the HDM SLIT group and the placebo group, respectively, showed greater than or equal to 15-point decrease in SCORAD score (relative risk, 1.28; 95% CI, 0.89-1.83). Significant SCORAD score decreases from baseline of 55.6% and 34.5% in HDM SLIT and placebo groups (mean difference, 20.4; 95% CI, 3.89-37.3), significant objective SCORAD score decreases of 56.8% and 34.9% in HDM SLIT and placebo groups (mean difference, 21.3; 95% CI, 0.66-41.81), and more patients with Investigator's Global Assessment 0/1 in the HDM SLIT group as compared with the placebo group (14 of 35 vs 5 of 31; relative risk, 2.63; 95% CI, 1.09-6.39) were observed at 18 months. CONCLUSIONS: Our results suggest that HDM SLIT may be effective in HDM-sensitized patients as an add-on treatment for atopic dermatitis. (C) 2021 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma \& Immunology. (AU)

FAPESP's process: 19/26678-0 - Atopic dermatitis in Brazilian patients: genetic aspects, immune response and immunotherapy in mite allergic patients
Grantee:Luisa Karla de Paula Arruda
Support type: Regular Research Grants